Psychiatric treatment is gaining fresh attention as investors weigh higher global yields, mixed inflation trends and ongoing energy shocks. While broad markets react to shifting interest rate expectations and commodity driven inflation, psychedelic medicine has quietly moved from fringe idea to funded research program at major pharmaceutical groups.

This Psychedelic Stocks In The Space AbbVie Bet A Billion Dollars On screener focuses on companies where psychedelic drug pipelines are meaningful enough to matter, yet still sit within larger, diversified businesses. Below are 3 stocks from the list that stand out for closer research within this evolving theme.

Optimi Health (OPTH)

Overview: Optimi Health is a Canadian pharmaceutical and nutraceutical manufacturer that produces MDMA, psilocybin, psilocin and other psychedelic substances, along with functional mushroom products, for clinics, pharmacies, clinical trials and wellness customers, selling through distributors, brokers and online channels. Its operations span farming and processing raw mushroom biomass, extracting active compounds and turning them into finished drug products and supplements.

Operations: Optimi Health currently generates about CA$0.23m in revenue from farming, processing and distributing agrifood products.

Market Cap: CA$36.6m

Optimi Health sits at the manufacturing heart of the psychedelic theme, with a Health Canada licensed GMP facility supplying psilocybin capsules and extracts into real world treatment programs like Australia’s Authorized Prescriber scheme, where no serious adverse events have been reported over more than two years. Recent exports to Australia and the UK, new microdose products and an ibogaine initiative show a company aiming to turn regulatory openings into commercial orders, even as revenue remains below CA$1m and losses weigh on return on equity. 

For more insight, the most followed Simply Wall St Community Narrative on Optimi Health lays out the optimistic read in detail. Its author values the stock at US$11, roughly 141% above the recent price of US$4.57. The thesis rests on Optimi being one of the only licensed manufacturers already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, with two GMP facilities built for around 75% gross margins while current utilization still sits under 1%.

Optimi Health’s licensed GMP footprint and small current revenue base suggest a story that many investors may be underestimating. Walk through the analysis report for Optimi Health to see what could be quietly reshaping the risk reward profile.

AtaiBeckley (ATAI)

Overview: AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing psychedelic and non-hallucinogenic treatments for hard to treat mental health conditions, including treatment resistant depression, alcohol use disorder, social anxiety disorder and cognitive impairment linked to schizophrenia.

Operations: AtaiBeckley currently generates about US$3.5 million in revenue from its business of identifying and advancing mental health treatment candidates.

Market Cap: US$1.91b

AtaiBeckley is positioned at the center of the psychedelic medicine theme with multiple Phase 2 programs that target treatment resistant depression, major depressive disorder and social anxiety. Even modest clinical success across VLS-01, BPL-003 or EMP-01 could influence its future. The trade off is clear: current revenue is small, losses are widening and the stock carries high funding and dilution risk, with a rich P/B multiple and a volatile trading profile. Upcoming Phase IIb data in 2026, potential progression to Phase 3 trials and growing institutional visibility through Russell index inclusion may provide AtaiBeckley with several potential catalysts over the next few years. Investors weighing the tension between clinical prospects and financial risk may want to review what the market could be overlooking.

AtaiBeckley’s expanding psychedelic pipeline and tiny current revenue base suggest the story investors see today may only be half complete, so walk through the 1 key reward and 4 important warning signs (1 is major!) and see what might be hiding in plain sight.

COMPASS Pathways (CMPS)

Overview: COMPASS Pathways is a biotechnology company focused on developing COMP360, a psilocybin based therapy being tested in Phase III trials for treatment resistant depression and in Phase II trials for post traumatic stress disorder and anorexia nervosa, primarily in the United Kingdom and United States.

Market Cap: US$1.75b

COMPASS Pathways provides concentrated exposure to one of the more advanced psychedelic drug development programs. COMP360 is already in Phase III for treatment resistant depression and the company has a stated plan to file a rolling NDA with the FDA. Recent six month Phase III data have been viewed positively by multiple analysts, who see a potential opportunity if the therapy fits into the existing network of roughly 6,000 interventional psychiatry sites. At the same time, the company is still pre revenue, is expected to remain loss making for several years, and has a history of shareholder dilution, so funding and execution risks are present. For investors weighing these trade offs, the current analyst debate and wide range of price targets suggest that an important part of the COMPASS Pathways narrative may not be immediately visible.

COMPASS Pathways sits at the crossroads of late stage trials and zero current revenue, and the real tension is growth expectations vs funding risk. Walk through the analyst forecasts for COMPASS Pathways to see what the market might be missing.

These three psychedelic stocks are just the entry point. The full Psychedelic Stocks In The Space AbbVie Bet A Billion Dollars On screener surfaced 24 more companies with equally compelling narratives that could influence how you think about mental health exposure in your portfolio, so take a look at the broader opportunity set with the Psychedelic Stocks In The Space AbbVie Bet A Billion Dollars On screener . Use Simply Wall St to identify and analyze the specific catalysts, clinical milestones and financial profiles that are most relevant to you so you can focus on the ideas within this theme that you find most compelling.

Take Control of Your Investment Journey

If Optimi Health or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Markets move fast and the next breakout lists rarely stay under the radar for long. Before the best entries get caught by the crowd, scan these fresh ideas and act now.

1. Target steady income potential by reviewing 9 dividend fortresses that aim to keep cash flowing even when sentiment drops and volatility rises.
2. Spot early movers in frontier computing by checking 26 quantum computing stocks that could capture momentum long before quantum headlines go mainstream.
3. Zero in on resilient balance sheets using the list of solid balance sheet and fundamentals (47 results) and avoid getting caught holding weak businesses when conditions shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.